Tyra Biosciences (NASDAQ:TYRA) Stock Rating Lowered by Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other research analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday. Wedbush upped their target price on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Finally, Piper Sandler increased their price target on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average price target of $36.00.

Tyra Biosciences Trading Down 1.7%

NASDAQ TYRA opened at $30.37 on Friday. Tyra Biosciences has a 12-month low of $6.42 and a 12-month high of $31.56. The company has a fifty day simple moving average of $24.66 and a two-hundred day simple moving average of $16.77. The stock has a market cap of $1.62 billion, a P/E ratio of -16.24 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.50). As a group, sell-side analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the director owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. The trade was a 0.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.20% of the company’s stock.

Institutional Trading of Tyra Biosciences

Institutional investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio increased its stake in shares of Tyra Biosciences by 34.8% during the third quarter. Public Employees Retirement System of Ohio now owns 24,962 shares of the company’s stock worth $349,000 after purchasing an additional 6,450 shares in the last quarter. HighVista Strategies LLC boosted its holdings in Tyra Biosciences by 163.6% in the 3rd quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock worth $921,000 after buying an additional 40,850 shares during the last quarter. Commodore Capital LP increased its stake in Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after buying an additional 275,000 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in Tyra Biosciences during the 3rd quarter worth approximately $2,612,000. Finally, Ameriprise Financial Inc. raised its holdings in shares of Tyra Biosciences by 8.1% during the third quarter. Ameriprise Financial Inc. now owns 87,107 shares of the company’s stock valued at $1,219,000 after acquiring an additional 6,505 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.